卡培他滨联合奥沙利铂对胃癌患者多项血清因子水平的影响

Influence of Capecitabine Combined with Oxaliplatin on the Serum Factor in Patients with Gastric Cancer

目的:探讨卡培他滨联合奥沙利铂对胃癌患者多项血清因子水平的影响。方法:选取2008年3月～2009年12月于我院进行治疗的80例胃癌患者为研究对象,将其随机分为A组(卡培他滨联合奥沙利铂组)40例和B组(氟尿嘧啶联合奥沙利铂组)40例,同时选取40例健康志愿者为对照组(C组)。记录所有患者的治疗效果及治疗前后的血清溶性细胞间黏附分子-1(sI-CAM-1)、一氧化氮(NO)、志愿者血管内皮细胞生长因子(VEGF)、白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)的水平。结果:治疗前A、B组的血清sICAM-1、NO、VEGF、IL-2、TNF-α和IL-6水平均显著高于C组(P<0.05),治疗后A组的治疗效果优于B组,且A组的血清sICAM-1、NO、VEGF、IL-2、TNF-α和IL-6的水平均低于B组,差异有统计学意义(P<0.05或P<0.01)。结论:卡培他滨联合奥沙利铂对胃癌患者多项血清因子水平的影响较大,效果明显。

OBJECTIVE：To study the influence of capecitabine combined with oxaliplatin on the serum factor in patients with gastric cancer.METHODS：80 patients with gastric cancer in our hospital from March 2008 to December 2009 were selected as research object,and they were randomly divided into group A（capecitabine combined with oxaliplatin group）40 cases and group B（fluorouracil combined with oxaliplatin group）40 cases,and 40 healthy volunteers were selected as control group（group C）.The serum levels of sICAM-1,NO,VEGF,IL-2,TNF-α and IL-6 of 2 groups before and after treatment were detected and compared.RESULTS：The serum levels of sICAM-1,NO,VEGF,IL-2,TNF-αand IL-6 in group A and group B before treatment were higher than in group C（P0.05）.The Therapeutic efficacy of group A was better than that of group B.Moreover,the serum levels of sICAM-1,NO,VEGF,IL-2,TNF-α and IL-6 in group A were all lower than in group B,there were significant differences（P0.05 or P0.01）.CONCLUSION：Capecitabine combined with oxaliplatin influence the serum factor in patients with gastric cancer significantly.Obvious therapeutic efficacy has been achieved and it is worthy of spreading in the clinic.